ProQR Operating Income from 2010 to 2026

PRQR Stock  USD 1.51  0.07  4.86%   
ProQR Therapeutics Operating Income yearly trend continues to be relatively stable with very little volatility. Operating Income is likely to drop to about -28.8 M. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit ProQR Therapeutics BV generates from its operations. View All Fundamentals
 
Operating Income  
First Reported
2012-12-31
Previous Quarter
-12.2 M
Current Value
-11.3 M
Quarterly Volatility
4.6 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check ProQR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProQR Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Total Revenue of 22.8 M or Research Development of 31.2 M, as well as many indicators such as Price To Sales Ratio of 12.08, Dividend Yield of 0.0 or PTB Ratio of 2.23. ProQR financial statements analysis is a perfect complement when working with ProQR Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with ProQR Stock
Check out the analysis of ProQR Therapeutics Correlation against competitors.
Evaluating ProQR Therapeutics's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into ProQR Therapeutics BV's fundamental strength.

Latest ProQR Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of ProQR Therapeutics BV over the last few years. Operating Income is the amount of profit realized from ProQR Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ProQR Therapeutics BV is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. ProQR Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProQR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Income10 Years Trend
Slightly volatile
   Operating Income   
       Timeline  

ProQR Operating Income Regression Statistics

Arithmetic Mean(30,206,932)
Coefficient Of Variation(65.13)
Mean Deviation15,178,190
Median(30,472,000)
Standard Deviation19,672,490
Sample Variance387T
Range61.9M
R-Value(0.62)
Mean Square Error253.2T
R-Squared0.39
Significance0.01
Slope(2,422,071)
Total Sum of Squares6192.1T

ProQR Operating Income History

2026-28.8 M
2025-27.4 M
2024-30.5 M
2023-31.9 M
2022-65.2 M
2021-57.2 M
2020-42.4 M

Other Fundumenentals of ProQR Therapeutics

ProQR Therapeutics Operating Income component correlations

0.85-0.9-0.840.070.570.30.821.00.830.770.560.00.440.780.680.640.710.850.74
0.85-0.9-0.510.060.560.070.450.880.590.950.280.170.150.450.610.590.670.630.42
-0.9-0.90.71-0.14-0.47-0.04-0.67-0.92-0.79-0.88-0.61-0.09-0.33-0.61-0.63-0.6-0.65-0.71-0.63
-0.84-0.510.710.04-0.38-0.32-0.95-0.81-0.95-0.4-0.770.23-0.63-0.92-0.67-0.62-0.59-0.82-0.85
0.070.06-0.140.04-0.14-0.030.00.08-0.120.28-0.030.25-0.51-0.12-0.17-0.17-0.43-0.28-0.16
0.570.56-0.47-0.38-0.14-0.080.410.570.330.520.01-0.070.310.450.410.390.80.620.15
0.30.07-0.04-0.32-0.03-0.080.410.290.230.060.02-0.050.130.290.180.160.030.370.26
0.820.45-0.67-0.950.00.410.410.790.910.380.79-0.190.70.940.540.490.570.840.86
1.00.88-0.92-0.810.080.570.290.790.810.810.540.020.410.740.680.640.720.850.72
0.830.59-0.79-0.95-0.120.330.230.910.810.480.87-0.170.70.90.630.590.610.810.88
0.770.95-0.88-0.40.280.520.060.380.810.480.210.270.00.350.50.490.520.50.26
0.560.28-0.61-0.77-0.030.010.020.790.540.870.21-0.160.710.750.360.330.330.560.87
0.00.17-0.090.230.25-0.07-0.05-0.190.02-0.170.27-0.16-0.29-0.19-0.13-0.11-0.2-0.23-0.19
0.440.15-0.33-0.63-0.510.310.130.70.410.70.00.71-0.290.750.180.150.580.670.77
0.780.45-0.61-0.92-0.120.450.290.940.740.90.350.75-0.190.750.50.450.550.760.82
0.680.61-0.63-0.67-0.170.410.180.540.680.630.50.36-0.130.180.51.00.660.710.44
0.640.59-0.6-0.62-0.170.390.160.490.640.590.490.33-0.110.150.451.00.640.670.39
0.710.67-0.65-0.59-0.430.80.030.570.720.610.520.33-0.20.580.550.660.640.890.51
0.850.63-0.71-0.82-0.280.620.370.840.850.810.50.56-0.230.670.760.710.670.890.76
0.740.42-0.63-0.85-0.160.150.260.860.720.880.260.87-0.190.770.820.440.390.510.76
Click cells to compare fundamentals

About ProQR Therapeutics Financial Statements

ProQR Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although ProQR Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ProQR Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ProQR Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Income-27.4 M-28.8 M

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProQR Stock

  0.74OSE OSE Pharma SAPairCorr

Moving against ProQR Stock

  0.818VP1 AVRICORE HEALTH INCPairCorr
  0.73VALN Valneva SE ADRPairCorr
  0.72GXEA Galapagos NVPairCorr
  0.7DNTH Dianthus TherapeuticsPairCorr
  0.59DNLI Denali Therapeutics Earnings Call This WeekPairCorr
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.